Astria Therapeutics
- Biotech or pharma, therapeutic R&D
Astria (Nasdaq: ATXS) is developing differentiated therapeutics for patients with allergic and immunological diseases. Astria's lead therapeutic is Navenibart which is currently in a global pivotal phase 3 trial for the rare disease hereditary angioedema. Astria's second public therapeutic is STAR-0310 which is in a phase 1a study, and may be developed for Atopic Dermatitis and a range of additional immunological disorders. Both of these therapeutics in development contain our signature half-life extended technology to enable transform the patient's experience, while focusing on proven clinically validated targets to ensure efficacy and maintain safety.
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}